

Axaron Bioscience AG

[View the current Axaron Bioscience AG Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/19021-Axaron+Bioscience+AG.html)

(<http://www.bioportfolio.com/biocorporate/19021-Axaron+Bioscience+AG.html>)

Contact Details:

**Im Neuenheimer Feld 515
Heidelberg**

Tel: 49 (0) 6221 454 6

Fax: 49 (0) 6221 454 700

Email: contact@axaron.com

69120

Germany

Axaron Bioscience AG is a biotech company that aims to develop drugs which address the large-volume and fast growing neurodegenerative disorders market. The company has built an attractive portfolio of compounds focused on the treatment of stroke, Spinal Cord Injury (SCI), ALS (Amyotrophic Lateral Sclerosis) and Parkinson's disease. The most advanced drug candidate AX200 has already entered phase II stroke trials at the end of 2004. Another compound, AX201 is scheduled for phase II clinical trials for stroke in 2006. Based on its proprietary D FINE platform, Axaron is able to quickly identify and develop drugs with neuroprotective or neuroregenerative properties. This enables the company to generate a constant flow of new drug candidates.

Recent Publications by Axaron Bioscience AG:



- [iGentfier: indexing and large-scale profiling of unknown transcriptomes.](#)
Development and refinement of methods to analyse differential gene... 15th September, 2007
Gentana GmbH, Axaron Bioscience AG, Im Neuenheimer Feld 515, D-69120- Nucleic Acids Res. 2007;35(14):4640-8. Epub 2007 Jun 25. ([DOI Direct Link](#))
- [An extended window of opportunity for G-CSF treatment in cerebral ischemia.](#)
BACKGROUND: Granulocyte-colony stimulating factor (G-CSF) is known as a... 9th December, 2006
Axaron Bioscience AG, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany.- BMC Biol. 2006 Oct 18;4:36. ([DOI Direct Link](#))
- [Long-term gene expression changes in the cortex following cortical ischemia revealed by transcriptional profiling.](#)
Cerebral ischemia evokes changes in gene expression time-dependently after... 6th September, 2006
Department of Molecular Neurology, Axaron Bioscience AG, Im Neuenheimer- Exp Neurol. 2006 Jul;200(1):135-52. Epub 2006 Mar 10. ([DOI Direct Link](#))

- [Effects of antidepressant treatment on gene expression profile in mouse brain: cell type-specific transcription profiling using laser microdissection and microarray analysis.](#)
*A gene expression study of mice treated with the tricyclic antidepressant...*24th May, 2006
AXARON Bioscience AG, Heidelberg, Germany.- J Neurochem. 2006 Apr;97 Suppl 1:44-9. ([DOI Direct Link](#))
- [A role for G-CSF \(granulocyte-colony stimulating factor\) in the central nervous system.](#)
*G-CSF (Granulocyte-colony stimulating factor) is a hematopoietic growth...*5th May, 2006
Axaron Bioscience- Cell Cycle. 2005 Dec;4(12):1753-7. Epub 2005 Dec 27.
- [Laser microdissection in CNS research.](#)
*The complexity of the brain makes the investigation of anatomically...*22nd October, 2005
Axaron Bioscience AG, Im Neuenheimer Feld 515, D-69120 Heidelberg,- Drug Discov Today. 2005 Sep 1;10(17):1167-74. ([DOI Direct Link](#))
- [The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis.](#)
*G-CSF is a potent hematopoietic factor that enhances survival and drives...*12th October, 2005
Axaron Bioscience- J Clin Invest. 2005 Aug;115(8):2083-98. Epub 2005 Jul 7. ([DOI Direct Link](#))
- [Identification of regulated genes during transient cortical ischemia in mice by restriction-mediated differential display \(RMDD\).](#)
*Cerebral ischemia induces transcriptional changes in a number of...*29th June, 2004
Department of Molecular Neurology and Technology, Axaron Bioscience AG, Im- Brain Res Mol Brain Res. 2004 Apr 29;124(1):20-8. ([DOI Direct Link](#))
- [Identification of regulated genes during permanent focal cerebral ischaemia: characterization of the protein kinase 9b5/MARKL1/MARK4.](#)
*Cerebral ischaemia induces transcriptional changes in a number of...*31st March, 2004
Axaron Bioscience- J Neurochem. 2004 Mar;88(5):1114-26.
- [Restriction-mediated differential display \(RMDD\) identifies pip92 as a pro-apoptotic gene product induced during focal cerebral ischemia.](#)
*Studies of gene expression changes after cerebral ischemia can provide...*20th March, 2004
Department of Molecular Neurology, Axaron Bioscience AG, Im Neuenheimer- J Cereb Blood Flow Metab. 2004 Feb;24(2):224-36. ([DOI Direct Link](#))
- [Macroresults for microarrays--an array of possibilities.](#)
*Studies of gene expression changes after cerebral ischemia can provide...*17th September, 2003
Axaron Bioscience AG, Im Neuenheimer Feld 515, D-69120 Heidelberg,- Pharmacogenomics. 2003 Jul;4(4):379-81. ([DOI Direct Link](#))
- [Generation and screening of a modular human scFv expression library from multiple donors.](#)
*Transcriptomics has become an important tool for the large-scale analysis...*29th May, 2003
Department of Technology, Axaron Bioscience AG, Heidelberg, Germany.- Methods Mol Biol. 2003;207:103-21.
- [Yellow pages to the transcriptome.](#)
*Transcriptomics has become an important tool for the large-scale analysis...*22nd April, 2003
Axaron Bioscience AG, Im Neuenheimer Feld 515, D-69120 Heidelberg,- Pharmacogenomics. 2002 Nov;3(6):791-807. ([DOI Direct Link](#))
- [Genome-wide transcription profiling of Corynebacterium glutamicum after heat shock and during growth on acetate and glucose.](#)
*To monitor the global gene expression of Corynebacterium glutamicum we...*18th October, 2002
Axaron Bioscience AG, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany.- J Biotechnol. 2002 Sep 25;98(2-3):255-68.

Press Releases on Axaron Bioscience AG:

[EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus](#)

6th November, 2009 EUCODIS Bioscience

VIENNA, Austria, November 6 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry announced today that it has

[Reportlinker Adds Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads](#)

5th November, 2009 Reportlinker

NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads

[Biosciences Firm Goes Live With CloudCraze Framework for eCommerce](#)

5th November, 2009 EDL Consulting

CHICAGO and LINCOLN, Neb., Nov. 5 /PRNewswire/ -- EDL Consulting, a leading technology services firm today announced that LI-COR Bioscience's biotech reagents and consumables and environmental

[NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations](#)

4th November, 2009 NeoStem, Inc.

NEW YORK, Nov. 4 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), announced today that Edward C. Geehr, M.D. has been named to the Company's Board of Directors. Dr. Geehr brings RESTON, Va. and MT.

[comScore Announces Availability of comScore/ImpactRx Physician Behavioral Measurement\(TM\) Solution](#)

2nd November, 2009 comScore, Inc.

LAUREL, N.J., Nov. 2 /PRNewswire-FirstCall/ -- comScore, Inc. (Nasdaq: SCOR), a leader in measuring the digital world, and ImpactRx, a pharmaceutical insights company, today

BioNews Results for Axaron Bioscience AG



- [ADDING and REPLACING INVO Bioscience Announces Clinical Results of Initial INVO Procedures in Latin America](#)

- Individual.com: Oct 29 2009 2:02AM Matching: bioscience ag*
- [ADDING and REPLACING INVO Bioscience Announces Clinical Results of Initial INVO Procedures in Latin America](#)
NewsBlaze: Oct 28 2009 8:34PM Matching: bioscience ag
 - [ADDING and REPLACING INVO Bioscience Announces Clinical Results of Initial INVO Procedures in Latin America](#)
FinanzNachrichten.de: Oct 28 2009 8:19PM Matching: bioscience ag
 - [ADDING and REPLACING INVO Bioscience Announces Clinical Results of Initial INVO Procedures in Latin America](#)
Yahoo! Canada: Oct 28 2009 11:25PM Matching: bioscience ag
 - [ADDING and REPLACING INVO Bioscience Announces Clinical Results of Initial INVO Procedures in Latin America](#)
Earthtimes.org: Oct 28 2009 8:43PM Matching: bioscience ag
 - [ADDING and REPLACING INVO Bioscience Announces Clinical Results of Initial INVO Procedures in Latin America](#)
Business Wire: Oct 28 2009 8:26PM Matching: bioscience ag
 - [INVO Bioscience Announces Clinical Results of Initial INVO Procedures in Latin America](#)
PharmiWeb: Oct 28 2009 4:51PM Matching: bioscience ag
 - [INVO Bioscience Announces Clinical Results of Initial INVO Procedures in Latin America](#)
Individual.com: Oct 28 2009 7:08PM Matching: bioscience ag
 - [Clinical results of INVO procedure for treatment of infertility announced](#)
News-Medical.Net: Oct 28 2009 7:15AM Matching: bioscience ag
 - [INVO Bioscience Announces Clinical Results of Initial INVO Procedures in Latin America](#)
NewsBlaze: Oct 27 2009 6:11PM Matching: bioscience ag
 - [INVO Bioscience Announces Clinical Results of Initial INVO Procedures in Latin America](#)
Forbes.com: Oct 27 2009 6:32PM Matching: bioscience ag
 - [INVO Bioscience Announces Clinical Results of Initial INVO Procedures in Latin America](#)
Street Insider: Oct 27 2009 6:25PM Matching: bioscience ag
 - [INVO Bioscience Announces Clinical Results of Initial INVO Procedures in Latin America](#)
Reuters: Oct 27 2009 6:19PM Matching: bioscience ag
 - [INVO Bioscience Announces Clinical Results of Initial INVO Procedures in Latin America](#)
FinanzNachrichten.de: Oct 27 2009 6:14PM Matching: bioscience ag
 - [INVO Bioscience Announces Clinical Results of Initial INVO Procedures in Latin America](#)
RBC Dain Rauscher: Oct 27 2009 6:06PM Matching: bioscience ag

Axaron Bioscience AG Clinical Trials:



- [Treatment With AX200 for Acute Ischemic Stroke](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services.

BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

